NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02075840,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,https://clinicaltrials.gov/study/NCT02075840,ALEX,ACTIVE_NOT_RECRUITING,"This randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naive anaplastic lymphoma kinase-positive (ALK-positive) advanced non-small cell lung cancer (NSCLC). Participants will be randomized in a 1:1 ratio to receive either alectinib, 600 milligrams (mg) orally twice daily (BID), or crizotinib, 250 mg orally BID. Participants will receive treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death. The study is expected to last approximately 144 months.",YES,Non-Small Cell Lung Cancer,DRUG: Alectinib|DRUG: Crizotinib,"Progression-Free Survival (PFS) by Investigator Assessment, PFS was assessed as time to disease progression or death whichever occurred first by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions., Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|Percentage of Participants With PFS Event by Investigator Assessment, PFS was assessed percentage of participants with disease progression or death whichever occurred first by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions., Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","PFS Independent Review Committee (IRC)-Assessed, PFS was assessed as time to disease progression or death whichever occurred first by IRC assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions., Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|Percentage of Participants With PFS Event by IRC, PFS was assessed as percentage of participants with disease progression or death whichever occurred first by IRC assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions., Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria, CNS progression was assessed as percentage of participants with an event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib., Randomization to CNS PD as first occurrence of disease progression (assessed every 8 weeks up to 33 months)|Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria, CNS progression was assessed as percentage of participants with event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib., Randomization to the first occurrence of disease progression in the CNS (assessed every 8 weeks up to 33 months)|Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria, ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters., Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|Duration of Response (DOR) According to RECIST V1.1 Criteria as Assessed by the Investigators, DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR., First occurrence of objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|Overall Survival (OS), Overall survival (OS) was defined as the time from randomization to death from any cause., From randomization until death (up to 43 months)|Percentage of Participants With OS Event, Overall survival (OS) was defined as the time from randomization to death from any cause., From randomization until death (up to 43 months)|Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria, CNS ORR was defined as the percentage of participants who attained CR or PR and had measurable/non-measurable CNS lesions at baseline. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters., Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|CNS DOR IRC-assessed According to RECIST v1.1 Criteria, CNS DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR., First occurrence of CNS objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)|Percentage of Participants With Adverse Events, An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., Baseline up to 28 months in the crizotinib arm and up to 30 months in the alectinib arm|Area Under The Concentration-Time Curve (AUC) of Alectinib, Pre-dose (within 2 hours before alectinib) (baseline), 1, 2, 4, 6, and 8 hours post-dose at Visit 0 (first dosing day) and Week 4; Pre-dose (within 2 hours) at Week 8, then every 8 weeks until disease progression or death/withdrawal (up to 33 months)|Maximum Concentration (Cmax) of Alectinib, Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)|Time to Reach Cmax (Tmax) of Alectinib, Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)|AUC of Alectinib Metabolite, Pre-dose (within 2 hours before alectinib) (baseline), 1, 2, 4, 6, and 8 hours post-dose at Visit 0 (first dosing day) and Week 4; Pre-dose (within 2 hours) at Week 8, then every 8 weeks until disease progression or death/withdrawal (up to 33 months)|Cmax of Alectinib Metabolite, Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)|Tmax of Alectinib Metabolite, Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)|Time to Deterioration by European Organization for The Research And Treatment of Cancer (EORTC) Quality Of Life Questionnaire Core 30 (C30), The EORTC QLQ-30 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in global health status or function is defined as a \>or=10-point decrease from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \>or=10-point decrease from baseline followed by death within 5 weeks from the last assessment., Baseline, every 4 weeks until disease progression (up to 33 months)|Percentage of Participants With Deterioration by EORTC Quality Of Life Questionnaire Core 30 (C30), The EORTC QLQ-30 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in global health status or function is defined as a \>or=10-point decrease from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \>or=10-point decrease from baseline followed by death within 5 weeks from the last assessment., Baseline, every 4 weeks until disease progression (up to 33 months)|Time to Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13), The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a \>or=10-point increase from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \>or=10-point increase above baseline followed by death within 5 weeks from the last assessment., Baseline, every 4 weeks until disease progression (up to 33 months)|Percentage of Participants With Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13), The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a \>or=10-point increase from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \>or=10-point increase above baseline followed by death within 5 weeks from the last assessment., Baseline, every 4 weeks until disease progression (up to 33 months)|Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score, The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning., Baseline, every 4 weeks until disease progression (up to 33 months)|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing, The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning., Baseline, every 4 weeks until disease progression (up to 33 months)|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Dyspnoea, The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning., Baseline, every 4 weeks until disease progression (up to 33 months)|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Chest, The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning., Baseline, every 4 weeks until disease progression (up to 33 months)|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Arm and Shoulder, The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning., Baseline, every 4 weeks until disease progression (up to 33 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,303,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BO28984|2013-004133-33,2014-08-19,2017-02-09,2026-09-29,2014-03-03,2018-03-15,2025-03-25,"North Valley Hem Onc Med Grp, Northridge, California, 91325, United States|TMPN/ Cancer Care Associates, Redondo Beach, California, 90277, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|University of Miami-Deerfield Beach, Deerfield Beach, Florida, 33442, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, 02215, United States|Dana Farber Can Ins, Boston, Massachusetts, 02215, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Washington Uni School of Medicine, Saint Louis, Missouri, 63110, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Kinghorn Cancer Centre, Darlinghurst, New South Wales, 2010, Australia|Royal North Shore Hospital, St Leonards, New South Wales, 2065, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Queen Elizabeth Hospital, Adelaide, South Australia, 5011, Australia|Monash Health Translational Precinct, Victoria, 3168, Australia|University Clinical Center Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo, 01246-000, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada|Centro Internacional de Estudios Clínicos (CIEC), Santiago, 8420383, Chile|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China|Shanghai Pulmonary Hospital, Shanghai, 200433, China|Clinica CIMCA, San Jose, 10103, Costa Rica|Kasr Eieny Uni Hospital, Cairo, 11555, Egypt|Chu Grenoble - Hopital Albert Michallon, Grenoble, 38043, France|CHRU de Lille, Lille, 59037, France|Centre Leon Berard, Lyon, 69373, France|Hopital Haut Leveque, Pessac, 33604, France|Grupo Angeles, Guatemala City, 01015, Guatemala|Tuen Mun Hospital, Hong Kong, 852, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hosp, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Rambam Medical Center, Haifa, 4959381, Israel|Meir Medical Center, Kfar Saba, 44281, Israel|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, 43100, Italy|Ospedale Provinciale Santa Maria Delle Croci, Ravenna, Emilia-Romagna, 48100, Italy|Policlinico Umberto i di Roma, Roma, Lazio, 00161, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO), Milano, Lombardia, 20141, Italy|Az. Osp. S. Luigi Gonzaga, Orbassano, Piemonte, 10043, Italy|Irccs Ist. Tumori Giovanni Paolo Ii, Bari, Puglia, 70124, Italy|Az Ospedaliera Nuovo Garibaldi Quartiere Nesima, Catania, Sicilia, 95122, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia, Perugia, Umbria, 06156, Italy|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Instituto Nacional De Enfermedades Respiratorias, Ciudad de México, Mexico CITY (federal District), 14080, Mexico|Uni of Auckland, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne, Gda?sk, 80-214, Poland|Ms Clinsearch Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej, Lublin, 20-064, Poland|Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie, Olsztyn, 10-357, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy, Otwock, 05-400, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie, Warszawa, 02-781, Poland|CHUC - Unidade de Pneumologia Oncológica, Coimbra, 3000-075, Portugal|IPO de Lisboa, Lisboa, 1099-023, Portugal|IPO do Porto, Porto, 4200-072, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|SPb City Clin Onc Dsp, Sankt-peterburg, Sankt Petersburg, 197022, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov, St. Petersburg, Sankt Petersburg, 197758, Russian Federation|N.N.Burdenko Main Military Clinical Hospital, Moscow, 105229, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, 21204, Serbia|National University Hospital, Singapore, 119228, Singapore|National Cancer Centre, Singapore, 169610, Singapore|Hospital General Univ. de Alicante, Alicante, 3010, Spain|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, 08916, Spain|Hospital Universitario Puerta de Hierro, Madrid, 28222, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Universitaetsspital Basel, Basel, 4031, Switzerland|Inselspital Bern, Bern, 3010, Switzerland|CHUV, Lausanne, 1011, Switzerland|UniversitätsSpital Zürich, Zürich, 8091, Switzerland|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung Univ Hosp, Tainan, 00704, Taiwan|National Taiwan University Hospital, Taipei, 00100, Taiwan|Taipei Veterans General Hospital, Taipei, 00112, Taiwan|National Cancer Inst., Bangkok, 10400, Thailand|Chiang Rai Prachanukroh Hospital, Chiang Rai, 57000, Thailand|Khonkaen Hospital, Khonkaen, 40000, Thailand|King Chulalongkorn Memorial Hospital, Patumwan, 10330, Thailand|Songklanagarind Hospital, Songkla, 90110, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital, Adana, 01250, Turkey|Ankara University Medical Faculty, Ankara, 06100, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, 22770, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, 44280, Turkey|Kyiv Regional Oncological Dispensary, Kyiv, 04107, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, 79031, Ukraine|Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom|University College London Hospital, London, NW1 - 2PG, United Kingdom|Guys & St Thomas Hospital, London, SE1 9RT, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/40/NCT02075840/Prot_001.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/40/NCT02075840/SAP_000.pdf"
